Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 78

1.

US6 Gene Deletion in Herpes Simplex Virus Type 2 Enhances Dendritic Cell Function and T Cell Activation.

Retamal-Díaz A, Weiss KA, Tognarelli EI, Freire M, Bueno SM, Herold BC, Jacobs WR Jr, González PA.

Front Immunol. 2017 Nov 10;8:1523. doi: 10.3389/fimmu.2017.01523. eCollection 2017.

2.

A trivalent subunit antigen glycoprotein vaccine as immunotherapy for genital herpes in the guinea pig genital infection model.

Awasthi S, Hook LM, Shaw CE, Friedman HM.

Hum Vaccin Immunother. 2017 Dec 2;13(12):2785-2793. doi: 10.1080/21645515.2017.1323604. Epub 2017 May 8.

3.

A Comparative Analysis of Polymerase Chain Reaction and Direct Fluorescent Antibody Test for Diagnosis of Genital Herpes.

Patwardhan V, Bhalla P, Rawat D, Garg VK, Sardana K, Sethi S.

J Lab Physicians. 2017 Jan-Mar;9(1):53-56. doi: 10.4103/0974-2727.187929.

4.

Herpes Genitalis: Diagnosis, Treatment and Prevention.

Sauerbrei A.

Geburtshilfe Frauenheilkd. 2016 Dec;76(12):1310-1317. doi: 10.1055/s-0042-116494. Epub 2016 Oct 18. Review.

5.

HSV2 reactivation and myelitis following influenza vaccination.

Lieberman A, Curtis L.

Hum Vaccin Immunother. 2017 Mar 4;13(3):572-573. doi: 10.1080/21645515.2016.1235105.

6.

Optimal management of genital herpes: current perspectives.

Sauerbrei A.

Infect Drug Resist. 2016 Jun 13;9:129-41. doi: 10.2147/IDR.S96164. eCollection 2016. Review.

7.

Current Concepts for Genital Herpes Simplex Virus Infection: Diagnostics and Pathogenesis of Genital Tract Shedding.

Johnston C, Corey L.

Clin Microbiol Rev. 2016 Jan;29(1):149-61. doi: 10.1128/CMR.00043-15. Review.

8.

Global and Regional Estimates of Prevalent and Incident Herpes Simplex Virus Type 1 Infections in 2012.

Looker KJ, Magaret AS, May MT, Turner KM, Vickerman P, Gottlieb SL, Newman LM.

PLoS One. 2015 Oct 28;10(10):e0140765. doi: 10.1371/journal.pone.0140765. eCollection 2015.

9.

Seroprevalence of Herpes Simplex Virus Type 1 and 2 in Taiwan and Risk Factor Analysis, 2007.

Shen JH, Huang KY, Chao-Yu C, Chen CJ, Lin TY, Huang YC.

PLoS One. 2015 Aug 7;10(8):e0134178. doi: 10.1371/journal.pone.0134178. eCollection 2015.

10.

SR-2P vaginal microbicide gel provides protection against herpes simplex virus 2 when administered as a combined prophylactic and postexposure therapeutic.

Fields SA, Bhatia G, Fong JM, Liu M, Shankar GN.

Antimicrob Agents Chemother. 2015 Sep;59(9):5697-704. doi: 10.1128/AAC.00690-15. Epub 2015 Jul 6.

11.

Sexually transmitted diseases treatment guidelines, 2015.

Workowski KA, Bolan GA; Centers for Disease Control and Prevention.

MMWR Recomm Rep. 2015 Jun 5;64(RR-03):1-137. Erratum in: MMWR Recomm Rep. 2015 Aug 28;64(33):924.

12.

Evasion of early antiviral responses by herpes simplex viruses.

Suazo PA, Ibañez FJ, Retamal-Díaz AR, Paz-Fiblas MV, Bueno SM, Kalergis AM, González PA.

Mediators Inflamm. 2015;2015:593757. doi: 10.1155/2015/593757. Epub 2015 Mar 30. Review.

13.

Genital herpes: oral antiviral treatments.

Hollier LM, Eppes C.

BMJ Clin Evid. 2015 Apr 8;2015. pii: 1603. Review.

14.

Estimating the cost-effectiveness of pre-exposure prophylaxis to reduce HIV-1 and HSV-2 incidence in HIV-serodiscordant couples in South Africa.

Jewell BL, Cremin I, Pickles M, Celum C, Baeten JM, Delany-Moretlwe S, Hallett TB.

PLoS One. 2015 Jan 23;10(1):e0115511. doi: 10.1371/journal.pone.0115511. eCollection 2015.

15.

Global estimates of prevalent and incident herpes simplex virus type 2 infections in 2012.

Looker KJ, Magaret AS, Turner KM, Vickerman P, Gottlieb SL, Newman LM.

PLoS One. 2015 Jan 21;10(1):e114989. doi: 10.1371/journal.pone.0114989. eCollection 2015. Erratum in: PLoS One. 2015;10(5):e0128615.

16.

Herpes simplex virus type 2 serostatus is not associated with inflammatory or metabolic markers in antiretroviral therapy-treated HIV.

Tan DH, Raboud JM, Szadkowski L, Yi TJ, Shannon B, Kaul R, Liles WC, Walmsley SL.

AIDS Res Hum Retroviruses. 2015 Mar;31(3):276-81. doi: 10.1089/AID.2014.0183. Epub 2014 Dec 17.

17.
18.

Herpes simplex virus type 2 and HIV disease progression: a systematic review of observational studies.

Tan DH, Murphy K, Shah P, Walmsley SL.

BMC Infect Dis. 2013 Oct 28;13:502. doi: 10.1186/1471-2334-13-502. Review.

19.

Averting HIV infections in New York City: a modeling approach estimating the future impact of additional behavioral and biomedical HIV prevention strategies.

Kessler J, Myers JE, Nucifora KA, Mensah N, Kowalski A, Sweeney M, Toohey C, Khademi A, Shepard C, Cutler B, Braithwaite RS.

PLoS One. 2013 Sep 13;8(9):e73269. doi: 10.1371/journal.pone.0073269. eCollection 2013.

20.

Ocular and neural distribution of feline herpesvirus-1 during active and latent experimental infection in cats.

Townsend WM, Jacobi S, Tai SH, Kiupel M, Wise AG, Maes RK.

BMC Vet Res. 2013 Sep 22;9:185. doi: 10.1186/1746-6148-9-185.

Supplemental Content

Support Center